The digestive tract as the origin of systemic inflammation by unknown
REVIEW Open Access
The digestive tract as the origin of systemic
inflammation
Petrus R. de Jong1,2*, José M. González-Navajas3,4 and Nicolaas J. G. Jansen1
Abstract
Failure of gut homeostasis is an important factor in the pathogenesis and progression of systemic inflammation,
which can culminate in multiple organ failure and fatality. Pathogenic events in critically ill patients include
mesenteric hypoperfusion, dysregulation of gut motility, and failure of the gut barrier with resultant translocation
of luminal substrates. This is followed by the exacerbation of local and systemic immune responses. All these
events can contribute to pathogenic crosstalk between the gut, circulating cells, and other organs like the liver,
pancreas, and lungs. Here we review recent insights into the identity of the cellular and biochemical players from
the gut that have key roles in the pathogenic turn of events in these organ systems that derange the systemic
inflammatory homeostasis. In particular, we discuss the dangers from within the gastrointestinal tract, including
metabolic products from the liver (bile acids), digestive enzymes produced by the pancreas, and inflammatory
components of the mesenteric lymph.
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Background
Gastro-intestinal (G-I) pathology in the critically ill
patient mainly involves the small intestine. The inner
lining of the small intestine is covered by a single
layer of intestinal epithelial cells (IECs) and is organized
as crypts and villi. The crypts are mostly made up of
proliferating cells, whereas the villi are covered by fully
matured epithelial cells to provide 200–300 m2 of ab-
sorptive surface [1]. All IEC types derive from intestinal
stem cells that reside at the crypt bottom [2]. Precursor
cells differentiate into absorptive enterocytes or one of
the secretory cell types. Enterocytes are equipped with
microvilli and express nutrient transporters to maximize
the uptake of solutes, simple carbohydrates, and amino
acids. Secretory cells include mucus-producing Goblet
cells, antimicrobial peptide-producing Paneth cells, and
hormone-producing enteroendocrine cells [3]. Products
released by secretory cell types are vital for the mainten-
ance of the gut barrier and motility. Paneth cells pro-
vide a protective niche for intestinal stem cells and
maintain homeostatic host–microbial interactions [4].
These cellular systems provide fail-safe mechanisms to
ensure continuous turnover of epithelial cells and
maintenance of the intestinal barrier.
The commensal microflora in a healthy gut constitute
approximately 103–104 different bacterial species, mostly
of the Firmicutes and Bacteroidetes phyla. They are indis-
pensable for the digestion of dietary substrates, exert
pro-proliferative effects on IECs, promote enterocyte
differentiation, prevent colonization of pathogens, and
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educate the mucosal and systemic immune system [5].
Furthermore, our microbiota is involved in the generation
of secondary bile acids, which promote the uptake of
dietary lipids and fat-soluble vitamins [6]. The fermen-
tation of complex carbohydrates yields short-chain fatty
acids (SCFAs; e.g., butyrate) that serve as an energy
source for the host and display beneficial effects on im-
mune cells [5], IEC proliferation, differentiation, and gut
barrier function [7]. Importantly, SCFAs also mediate
anti-inflammatory effects on immune cells, which involves
signaling via G-protein-coupled receptor 41 (GPR41) and
GPR43. GPR43 signaling is anti-inflammatory in the gut
[8]. However, GPR43 deficiency results in increased
mortality upon gut barrier loss, most likely due to sep-
tic complications of bacterial translocation associated
with aberrant neutrophil chemotaxis [9]. Thus, the in-
testinal microbiota and its metabolic products are vital
for gut homeostasis.
Systemic stress, such as major trauma, burns, or sur-
gery, can disturb this delicate balance, leading to epi-
thelial denudation of villi, enterocyte dysfunction, gut
barrier loss, and translocation of luminal constituents
to the circulation [10]. This may occur with only mild
systemic inflammation, for example, leakage of endo-
toxins (lipopolysaccharide (LPS)) from the intestinal
lumen to the circulation occurs during open heart sur-
gery [11]. On the other hand, a major shift of intestinal
microbiota to pathogenic species coinciding with reduced
microbial diversity occurs in both systemic inflammatory
response syndrome and neonatal sepsis patients [12]. Both
Gram-negative bacteria (e.g., Escherichia coli, Klebsiella,
Enterobacter spp.) and Gram-positive bacteria (e.g.,
Staphylococcus, Enterococcus, Streptococcus spp.) play a
role in bacteremia or sepsis in neonates [13], infants [14],
and adults [15]. Thus, a compromised gut barrier can lead
to bacterial translocation and bacteremia, which could
lead to systemic inflammation and, in susceptible patients,
to sepsis, septic shock, and circulatory collapse, with or
without multiple organ dysfunction syndrome (MODS).
The role of local events in the intestines, the importance
of the gut–liver axis, the contribution of biliary and pan-
creatic enzymes, and, finally, the gut–lung connection are
discussed in the sections below.
Gastrointestinal failure
The aforementioned deleterious events do not always
remain indolent and may lead to the poorly defined
clinical entity of G-I failure. Its symptoms include food
intolerance, G-I hemorrhage, and ileus. In more severe
cases, G-I failure may lead to liver failure, cholecystitis,
and pancreatitis [16, 17]. Postoperative patients frequently
experience intestinal failure of various degrees of severity
[18]. A grading system of acute G-I injury was recently
proposed with increasing severity from grade I (risk of
developing G-I dysfunction or failure), grade II (G-I dys-
function), grade III (G-I failure), to grade IV (G-I failure
with severe impact on distant organ function) [19]. Early
diagnosis of G-I failure is challenging as problems with
enteral feeding, including vomiting, delayed gastric empty-
ing, and diarrhea, can occur in up to 50 % of critically ill
patients [20]. Since enteral nutrition has beneficial effects
on the gut barrier, parenteral feeding may lead to further
deterioration of G-I physiology. Gut dysfunction and G-I
failure are associated with prolonged intensive care unit
(ICU) stay and increased mortality [21, 22]. In fact, the
presence of three or more G-I symptoms (high gastric
residual volume, absent bowel sounds, vomiting, diarrhea,
bowel distension, and G-I bleeding) on the first day of
ICU admission is associated with a threefold increase in
mortality [23]. To aid in the diagnosis of G-I failure,
plasma or urinary levels of intestinal fatty acid-binding
protein (I-FABP), liver fatty acid-binding protein (L-FABP)
and ileal bile acid-binding protein (I-BABP), and/or citrul-
line can be helpful [24, 25]. I-FABP, L-FABP, and I-BABP
are reliable biomarkers of enterocyte damage and/or loss
and their urinary or plasma levels increase during intes-
tinal injury. Plasma levels of citrulline represent enterocyte
mass and/or functionality [26]. In the course of G-I fail-
ure, plasma citrulline levels would therefore be decreased
and are indicative of a loss of the gut barrier [24, 27]. In-
deed, low citrulline levels are associated with elevated
serum C-reactive protein (CRP) levels, an increased rate
of nosocomial infections, and higher mortality in critically
ill patients [28]. A recent report showed that I-FABP
can serve as a biomarker for the intensity of intestinal
handling during surgery [29]. These serum markers also
demonstrated that gut barrier loss is prevalent in patients
that underwent non-abdominal surgery [30]. Finally, the
systemic release of I-FABP in the course of surgery coin-
cided with endotoxemia [31], whereas the administration
of endotoxin in healthy subjects induced an increased
intestinal permeability [32]. Together, these data further
support the association between gut barrier dysfunction
and systemic inflammation, as shown in Fig. 1.
Early event: loss of the gut barrier
The gut barrier must be permissible to allow uptake of
essential nutrients, but also needs to retain harmful sub-
stances that are only micrometers away from the circula-
tion. These include microbial substrates (e.g., LPS), dietary
components (e.g., free fatty acids (FFAs)) and digestive
enzymes produced by the exocrine pancreas. The main
etiological factors that contribute to gut barrier loss
after surgery are splanchnic hypoperfusion (including
ischemia/reperfusion damage) [30], decreased gut mo-
tility, and hypoxia. These processes are under control
of neuronal and endocrine effector arms, in addition to
local control mechanisms, which also affect the
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microcirculation. Hypotension associated with systemic
inflammatory response syndrome usually results in shunt-
ing of blood from the splanchnic vessels to the central cir-
culation. The perfusion of the small intestine operates
within tight margins; the lack of autoregulatory mecha-
nisms results in a hypersensitivity to variations in blood
pressure. The combination of hypoperfusion and hyp-
oxia can further exacerbate the deleterious effects on
intestinal tissue integrity [33]. Hypoperfusion and is-
chemia/reperfusion (I/R) injury are partners in crime
with regard to intestinal pathology [34], even though
the latter displays distinct features. Importantly, short
periods of I/R did not induce intestinal inflammatory
responses in human [35], suggesting that a certain thresh-
old of injury is required for the instigation of G-I failure.
An adequate microcirculation is also required for optimal
blood flow to tissues, particularly in the G-I tract. Various
clinical tools are available to monitor the microcirculation,
including orthogonal polarization spectral and sidestream
darkfield imaging [36]. Finally, the severity and/or dur-
ation of intestinal ischemia are directly correlated with the
degree of gut barrier loss and endothelial dysfunction [37].
The reticulo-endothelial system in the liver provides a fail-
safe mechanism to filter out any toxic translocation prod-
ucts from the portal circulation that leaked from the intes-
tines. However, Kupffer cells (KCs) of the liver—which are
key players in the reticulo-endothelial system—appear to
play a dual role in the regulation of inflammation.
Whereas KCs are an important source of pro-
inflammatory cytokines in systemic inflammation [38],
they may also play an anti-inflammatory role under these
conditions [39, 40]. Finally, a portion of potentially dele-
terious elements can also find a shortcut to the circulation
via the mesenteric lymph.
The gut–liver axis in systemic inflammation
The portal vein works as a major expressway from
the spleen and G-I tract to the liver, accounting for
Fig. 1 Pathogenic events in the course of gastro-intestinal failure. Potential toxic components in the small intestine are contained in the lumen
under homeostatic conditions, whilst enterocytes allow the uptake of nutrients such as short-chain fatty acids (SCFA) across the epithelial barrier.
In the critically ill patient suffering from major trauma or burns or undergoing surgery, protective mechanisms that maintain the gut barrier fail
due to circulatory and neuroendocrine dysregulation. This results in gastro-intestinal (G-I) failure, which coincides with clinical signs such as oral
intolerance, gastrointestinal hemorrhage, or ileus. G-I failure is a progressive clinical syndrome in which an early stage of predominantly gastrointestinal
symptoms may be followed by extraintestinal derangements, such as acute respiratory distress syndrome (ARDS), liver failure, cholecystitis, pancreatitis,
or kidney failure. G-I failure is associated with epithelial denudation, villus shortening, and inflammatory cell infiltration in the small intestine at the
tissue level. Finally, various clinical biomarkers may aid in the diagnosis of G-I failure, including plasma or urinary levels of intestinal-type fatty acid-
binding protein (I-FABP), liver-type fatty acid-binding protein (L-FABP), ileal bile acid-binding protein (I-BABP) or citrulline. CRP C-reactive protein
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approximately 70 % of the hepatic blood supply. This
anatomical situation makes the liver a central location
for clearing systemic bacterial infections and for main-
taining immune system homeostasis. Lining the hepatic
sinusoids, KCs are the first macrophage population to
encounter bacteria or microbial products derived from
the intestine. However, the function of KCs is compro-
mised in patients with advanced liver disease and, despite
the threatening consequences of impaired liver function,
systemic infections are the main cause of death in these
patients [41]. Many of these infections are initiated by
translocation of intestinal bacteria and usually result in
bacteremia and, in more severe cases, sepsis [42]. Bacterial
translocation can be demonstrated by analysis of mesen-
teric lymphatics or portal vein blood samples. It is import-
ant to point out here that, in a classic study, portal vein
sampling in trauma patients undergoing laparotomy did
not provide evidence for bacterial translocation by blood
cultures [43]. Subsequent studies with trauma patients
confirmed that blood cultures generally failed to show
bacterial growth [44, 45]. However, more sensitive methods,
such as immunostaining for E. coli beta-galactosidase [44]
or electron microscopy [45], provided direct evidence
for bacterial translocation to mesenteric lymph nodes
(MLNs) in most patients. While the presence of bac-
teria in MLNs as a pathological event has been debated
[46, 47], multiple studies have shown that positive cul-
tures from MLN samples obtained from laparotomy pa-
tients occurred in 10–15 % of patients, which correlated
with an increased risk of postoperative sepsis [48, 49] or
postoperative infection [50].
Both human and animal model studies have provided
more mechanistic details on gut–liver crosstalk (Table 1).
Bacteremia increases the risk of spontaneous bacterial
peritonitis, which occurs in one out of five hospitalized
cirrhotic patients [51]. At the same time, microbiota-
driven inflammation can also aggravate liver disease. For
example, alterations in colonic microbiota are associated
with endotoxemia and inflammation in patients with
hepatic encephalopathy, a complication of liver cirrhosis
[52, 53]. Gut bacteria dysbiosis may also contribute to
postoperative infections and organ rejection after liver
transplant [54]. In fact, acute liver rejection in rats is
accompanied by alterations in gut microbiota, impaired
integrity of the intestinal barrier, bacterial translocation,
elevation of plasma endotoxin levels, and a systemic in-
flammatory response [55, 56]. Gut microbiota dysbiosis
can also trigger local inflammation in the liver and promote
the progression from moderate liver disease to steatohepati-
tis [57]. A recent study showed that microbiota-dependent
activation of the chemokine receptor CX3CR1 in intestinal
macrophages is crucial for maintaining intestinal homeo-
stasis and barrier integrity and, therefore, for controlling
steatohepatitis progression [58]. Since advanced liver
disease usually leads to circulatory abnormalities (portal
hypertension, splanchnic vasodilation), these events may
constitute a vicious circle. Damage to the intestinal barrier
leads to bacterial translocation and thus liver inflamma-
tion and liver dysfunction, leading to exacerbation of
circulatory abnormalities and causing further intestinal
injury [59].
Emphasizing the relationship between microbiota and
the immune response in the liver, recent data suggest
that the liver remains sterile when the intestine is healthy.
However, the liver becomes an important “secondary fire-
wall” when commensal bacteria penetrate the mesenteric
Table 1 Gut-liver crosstalk in systemic inflammation
Major finding Study type Reference
Bacteremia due to bacterial translocation is associated with an increased risk of bacterial peritonitis Human [51]
Hepatic encephalopathy is associated with changes in the intestinal microbiota Human [52]
Acute liver rejection is associated with changes in intestinal microbiota, loss of gut barrier, and enhanced
systemic inflammation
Rodent [55, 56]
CX3CR1 signaling by intestinal macrophages regulates steatohepatitis Rodent [58]
A hepatic vascular and phagocytic network functions as a “secondary firewall” to filter escaped gut commensals Rodent [60]
Liver cirrhosis is associated with increased inflammasome activation in ascitic fluid macrophages Human [61]
Translocation of bacterial DNA in liver cirrhosis is associated with enhanced systemic inflammatory activity Human [62, 63]
Hepatic STAT3 signaling protects against systemic inflammation caused by polymicrobial sepsis Rodent [72]
Hepatic gp130-STAT3 signaling induces myeloid-derived suppressor cells that protect against polymicrobial sepsis Rodent [73]
Hepatic STAT3 signaling regulates cellular and humoral pulmonary immunity against bacterial infection Rodent [74]
The liver enhances and protects against systemic inflammation through Kupffer cell-mediated cytokine production
and detoxification by parenchymal cells, respectively
Rodent [76]
Kupffer cells aggravate lung damage in acute pancreatitis Rodent [78, 79]
Summary of key studies that addressed the bidirectional gut–liver crosstalk in the pathogenesis of systemic inflammation. The type of study (animal model or
human) is indicated
STAT3 signal transducer and activator of transcription 3
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circulation [60]. Importantly, not only viable bacteria
but also abnormal amounts of microbial products (e.g.,
LPS or bacterial DNA) can breach the intestine and ar-
rive at the liver or the ascitic fluid. These events have
been associated with activation of the inflammasome
complex [61], systemic inflammatory responses [62, 63],
and acute-on-chronic liver failure [64]. The microbial
antigens are recognized by pattern recognition receptors
(PRRs), namely Toll-like receptors (TLRs), which in the
liver are expressed on KCs, hepatic stellate cells, intrahe-
patic lymphocytes, dendritic cells, endothelial cells, and
hepatocytes [65]. TLR-mediated activation of hepatic
stellate cells is associated with the production of proin-
flammatory cytokines [66] and the development of liver
fibrosis [67]. KCs normally produce proinflammatory
cytokines and promote immune cell recruitment after
TLR stimulation; however, continuous stimulation of KCs
with low levels of LPS induces LPS tolerance and release
of anti-inflammatory cytokines such as interleukin (IL)-10
[68]. Furthermore, in the healthy liver LPS is detoxified by
both KCs and hepatocytes and rapidly loses its biological
activity. Thus, it has been speculated that activation of
TLR4 on KCs might be a common event and play a role
in immune homeostasis, whereas activation of other PRRs,
like NOD-like receptors, may be more frequent in infec-
tion [54]. Several studies also pointed to crosstalk between
KCs and migrating neutrophils. Bactericidal neutrophils
migrate to the liver sinusoids during endotoxemia and
sepsis and, along with KCs, form the leading force in the
elimination of bacteria in the liver [69]. In turn, elimin-
ation of neutrophils is necessary to resolve inflammation
and previous studies suggested that KCs ingest and elim-
inate neutrophils in the liver sinusoids after microbial
clearance [70]. These interactions may play a critical role
in downregulating pro-inflammatory cytokine and chemo-
kine production by KCs [71].
The liver also maintains immune homeostasis in other
organs, with an important role for hepatocyte signal trans-
ducer and activator of transcription 3 (STAT3) during
sepsis and pneumonia. Hepatic STAT3 activity was ne-
cessary to prevent an excessive systemic inflammatory
response and attenuate lethality after cecal ligation and
puncture-induced sepsis [72]. STAT3-mediated protection
in this model of polymicrobial sepsis was attributed to the
serum amyloid A and CXCL1-dependent mobilization of
myeloid-derived suppressor cells [73]. Similarly, a recent
study showed that pre-existing liver STAT3 activation
modulates host immune responses in a two-hit model of
endotoxemia followed by bacterial lung challenge [74].
Mice with hepatocyte-specific STAT3 deletion showed re-
duced concentrations of acute phase response proteins
serum amyloid A and serum amyloid P, impaired alveolar
macrophage reactive oxygen species generation, higher
lung and blood bacterial loads, and increased mortality in
this model [74]. Thus, physiological amounts of bacterial
ligands arriving at the liver from the gut can contribute to
maintain systemic immune homeostasis through the in-
duction of STAT3 activity. However, gut alterations and
excessive microbiota-dependent liver inflammation may
shift this balance towards a more proinflammatory
phenotype, leading to damage in remote organs such as
brain, lung, pancreas, and heart [75]. A good example
of this crosstalk is the gut–liver–lung axis during acute
pancreatitis, leading to the acute respiratory distress
syndrome (ARDS) and MODS. In this scenario, severe
pancreatitis triggers intestinal barrier dysfunction and
gut inflammation. Translocated microbial products and
inflammatory mediators produced in the gut (e.g.,
tumor necrosis factor (TNF)-α, IL-6, and IL-1β) then
arrive at the liver via the portal vein and activate KCs,
which produce more pro-inflammatory cytokines that
amplify the inflammatory response [76]. These cytokines
released by the liver are then transported via the systemic
circulation to the lung, where they cause acute
hemorrhagic necrosis of lung epithelial cells and activation
of pulmonary monocytes and macrophages, ultimately
contributing to ARDS and MODS [77, 78]. Indeed, inhib-
ition of KCs has been shown to reduce pancreatitis-
associated remote organ injury [78, 79]. Together, these
studies suggest that failure of the gut barrier may consti-
tute a fatal event in patients with end-stage liver disease
and that the “gut–liver inflammation” axis may play an
important role in the balance between tolerance and
systemic inflammation in critical illness.
Intestinal damage induced by bile acids
In addition to the liver serving as a secondary firewall,
there is strict compartmentalization of secretions of the
biliary tract and exocrine pancreas. Bile acids and pancre-
atic enzymes are excreted through the pancreatic duct to
promote the digestion and uptake of lipids, carbohydrates,
and amino acids. Primary bile acids are synthesized in the
liver as derivatives of cholesterol, e.g., cholic acid and che-
nodeoxycholic acid. These are converted by the intestinal
microflora to yield secondary bile acids, deoxycholic
acid (DCA), lithocholic acid, and ursodeoxycholic acid
(UDCA) [80]. Bile is released in the duodenal lumen in
response to cholecystokinin (CCK) produced by duodenal
cells postprandially [81]. The bile acids are reabsorbed
with dietary lipids and returned to the liver via the entero-
hepatic circulation, whereas saturated digestive enzymes
are normally excreted and eliminated [80]. However,
under certain conditions bile acids may pave the way
for proteases to breach the gut barrier and cause sys-
temic inflammatory responses. Importantly, the differ-
ent types of bile acids have differential effects on the
gut barrier. For example, whereas cholic acid, DCA,
and chenodeoxycholic acid showed disruptive effects
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on the intestinal epithelial barrier in vitro, this was not
the case for UDCA [82]. Furthermore, exposure of epi-
thelial cells to concentrations of DCA corresponding to
high-fat diets disrupted the epithelial barrier in vitro
and in vivo. In contrast, concentrations of DCA typic-
ally found in low-fat diets did not affect the epithelial
integrity [83]. In this context, the effects of enteral nutri-
tion versus total parenteral nutrition on the gut barrier in
critically ill patients are highly relevant. Total parenteral
nutrition increases the gut permeability, which in addition
to the effects of bile acids may involve a variety of mecha-
nisms [84]. Others showed protective effects of lipid-rich
enteral feeding on the gut barrier in experimental shock,
which was reversed by CCK receptor antagonists [85].
These data suggest an intrinsic protective effect of enteral
nutrition on the gut barrier. Thus, even though enteral
feeding stimulates the release of bile acids in the gut
lumen that could potentially damage the epithelial lining,
its advantageous effects on the gut barrier appear to be
dominant.
Intestinal and extra-intestinal injury caused by
pancreatic enzymes
The local and systemic effects of pancreatic enzymes in
the critically ill patient have recently regained attention.
Acinar cells of the exocrine pancreas secrete a variety
of enzymes that, upon activation in the duodenal
lumen, can degrade proteins (trypsinogen, chymotryp-
sinogen, carboxypeptidase, elastases), lipids (pancreatic
lipase, phospholipase), and sugars (pancreatic amylase).
Bicarbonate (HCO3
−) is produced by ductal cells. This
pancreatic juice is secreted in response to CCK. How-
ever, during intestinal ischemia these proteases can
contribute to degradation of the protective mucus layer
and epithelial tight-junctions, leading to an elevated gut
permeability and penetration of serine proteases of the
gut wall [86]. This was first demonstrated by pancreatic
duct ligation, which reduced gut barrier failure in an
experimental model of hemorrhage-associated shock
[87]. Prevention of pancreatic enzyme influx in the
intestinal lumen resulted in reduced degradation of the
mucus layer, less toxicity to endothelial cells, and reduced
activation of circulating neutrophils [87]. The toxic effects
of pancreatic enzymes in vivo, including trypsin, chymo-
trypsin, elastase, amylase, and lipase, are potentiated when
the mucus layer is already compromised [88]. Conversely,
the addition of a mucus layer to IEC monolayers reduced
the disruptive effects of trypsin on the gut barrier [89].
Importantly, the translocation of active proteases to the
circulation is associated with an increased risk of multi-
organ failure [90], most likely caused by local autodiges-
tive processes in the gut that liberate tissue or microbial
factors that turn on systemic inflammatory responses [91].
These data suggest that pharmacological inhibition of
pancreatic enzymes could abrogate these pathophysio-
logical events and ameliorate circulatory derangement in
critical illness. A recent publication demonstrated this con-
cept in three models of experimental shock in rats—hemor-
rhagic shock, peritonitis, and endotoxin shock—with a
focus on serine proteases. All models of shock resulted
in increased protease activity in the gut wall. Con-
versely, intraluminal administration of protease inhibitors
(ANGD, tranexamic acid, and aprotinin) dramatically re-
duced tissue damage in the small intestines as well as
distant organs (heart, lung), which was associated with
significantly improved survival [92]. Notably, direct and
invasive administration of protease inhibitors was required
to yield high intraluminal concentrations in the gut [92],
which limits its direct translation into clinical practice.
Alternatively, continuous delivery of protease inhibitors
via enteral feeding has been shown to be successful in one
case of septic shock [93]. Together, these data suggest that
under ischemic conditions in the gut, pancreatic enzymes
can mediate deleterious local and systemic effects in the
critically ill patient, as summarized in Fig. 2.
The gut–lung connection: mesenteric lymph
A direct anatomical link between the gut, systemic cir-
culation, and distant organs is provided by the lymphatic
vessels from the intestines. After feeding, the mesenteric
lymph is enriched for lipids (chylomicrons), fat-soluble
vitamins, and a variety of other lipophilic macromolecules.
These afferent lymphatic vessels drain from the intestinal
villus tips to MLNs and ultimately into the thoracic duct,
heart, and the pulmonary circulation. Within this net-
work, MLNs are the site where luminal antigens are
filtered and taken up by antigen-presenting cells (mac-
rophages, dendritic cells), which can direct adaptive
immune responses. The cellular players of this special-
ized mucosal immune system shuttle between MLNs
and the lamina propria and are programmed for suc-
cessful compartmentalization of the commensal micro-
flora. One of the mechanisms involved in this process
is the deposition of secretory IgA in the mucus layer
[94], an adaption to the unusually large bacterial load
of the G-I tract.
Mesenteric lymph avoids the portal circulation and
thus bypasses the reticulo-endothelial system in the liver,
i.e., the secondary firewall mediated by KCs. Any unfil-
tered luminal constituents, such as endotoxins and pan-
creatic enzymes, in addition to locally produced cytokines
and activated immune cells that exit the MLN, are able to
directly leak to the circulation. Cytotoxic factors from
mesenteric lymph will make their first pass through the
pulmonary circulation. Direct toxic effects on the pulmon-
ary endothelium can then cause acute lung injury, culmin-
ating in ARDS [95]. This is known as the gut–lymph–lung
axis. Indeed, abrogation of mesenteric lymph drainage
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prevented hemorrhagic shock-induced endothelial hyper-
permeability and lung damage [96]. Furthermore, real-
time cross-transfusion of mesenteric lymph from donor
rats with trauma/hemorrhagic shock to naïve recipients
resulted in marked lung injury and local neutrophil accu-
mulation in these recipients [97]. Virtually all studies that
have addressed the components of mesenteric lymph used
animal models (Table 2); there is little information regard-
ing the toxic components of post-shock mesenteric lymph
in human [98]. Bacteria or microbial products do not
play a role in this phenomenon [99]. Rather, various
acute-phase proteins, possibly produced by the intes-
tinal epithelium [100], in addition to pro-inflammatory
lipid mediators [101], and in particular lipase-generated
FFAs [102], are likely causative agents. Their cytotoxicity
appears to be determined by the FFA-to-protein ratio in
mesenteric lymph, as the addition of albumin—a lipid
scavenger—reversed their effects [102]. Serum albumin
precursor was the most (approximately eightfold) upregu-
lated protein in post-shock mesenteric lymph [100], which
could therefore be part of a compensatory mechanism to
inhibit lipid cytotoxicity [103]. On the other hand, gly-
cosylated albumin in post-shock mesenteric lymph has
been associated with intrinsic cytotoxicity [104]. Thus,
albumin can have both protective and deleterious ef-
fects on lung injury.
Another candidate to mediate the toxic effects of
mesenteric lymph is phospholipase A2 (PLA2), an en-
zyme that generates lipid mediators (eicosanoids, pros-
taglandins) [105]. Importantly, high levels of PLA2 are
synthesized and secreted by Paneth cells in the intestine
[106]. Another antimicrobial protein produced by Paneth
cells that was found to be increased in toxic mesenteric
lymph was α-defensin 4 [107]. Together, this suggests a
Fig. 2 Cellular and molecular players in intestinal injury caused by systemic inflammation. A large variety of pancreatic and hepatobiliary products
are involved in the complex digestive function of the small intestine, e.g., proteolytic enzymes, lipases, amylases, bicarbonate, and primary bile
acids. The primary bile acids (cholic acid, chenodeoxycholic acid) are converted to secondary bile acids (e.g., lithocholic acid, DCA, UDCA) by the
microbiota. The digestive enzymes derived from the host or microbiota ensure the breakdown of macromolecules to soluble nutrients, which is
followed by uptake and transport to the portal circulation or intestinal lymph tract. While the intestinal microflora are crucial for these digestive
functions in the lumen, their quantity and topography are tightly controlled by the thick mucus layer that contains secretory IgA and antimicrobial
peptides (e.g., defensins) produced by mucosal immune cells and the epithelium. In critical illness, circulatory derangement results in gut barrier loss
and the translocation of digestive enzymes, cytotoxic bile acids, free fatty acids (FFAs), and microbial substrates to the submucosa, which exacerbates
local and systemic inflammatory reactions. The intestinal epithelium is also an important source of pro-inflammatory mediators that are released into
the circulation, including IL-17, lipid mediators produced by phospholipase A2 (PLA2), and antimicrobial peptides derived from Paneth cells. These
pathogenic events also pave the way for cytotoxic components to directly leak from the intestinal lumen to mesenteric lymph vessels, which
constitutes the gut–lymph–lung axis. MLN mesenteric lymph node, MMP matrix metalloproteinase, PV portal vein, VC vena cava
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potential detrimental role for Paneth cell products in the
course of systemic inflammation and/or shock, which are
distributed via the intestinal lymphatic system to the cir-
culation. Indeed, mice deficient for matrix metalloprotein-
ase 7 (MMP7), the enzyme involved in posttranslational
activation of Paneth cells products, were protected against
systemic LPS-induced lethality [108]. Activation of Paneth
cells and transport of Paneth cell products, including
pro-inflammatory IL-17A, by intestinal macrophages to
the liver have been previously demonstrated in systemic
inflammation [109]. IL-17 is an important activator of
neutrophils and Paneth cells were the main producers
of IL-17 in an experimental model of TNF-α-induced
intestinal injury and shock [110]. Furthermore, liver I/R
injury and its associated systemic inflammation resulted
in significantly increased IL-17 levels in the portal ven-
ous blood, which was associated with massive Paneth
cell degranulation in the gut and hepatic, intestinal, and
Table 2 Gut–lung crosstalk
Major finding Study type Reference
Cross-transfusion of mesenteric lymph from donors after shock/trauma induces acute lung injury in recipients Rodent [97]
Post-shock mesenteric lymph contains increased amounts of bioactive lysophospholipids and PUFAs Rodent [101]
Post-shock mesenteric lymph contains increased amounts of free fatty acids Rodent [102]
The detrimental effects of post-shock mesenteric lymph can be reversed by the addition of albumin Rodent [103]
Inhibition of PLA2 inhibits the cytotoxic activity of post-shock mesenteric lymph Rodent [105]
Levels of Paneth cell-derived α-defensin 4 (an antimicrobial peptide) are increased in post-shock mesenteric lymph Rodent [107]
Endogenous alarmins are abundantly released from the intestines in post-shock mesenteric lymph Rodent [113]
Pertinent studies that addressed the interactions between intestinal pathology and lung injury
PLA2 phospholipase A2, PUFA poly-unsaturated fatty acids
Fig. 3 Direct and indirect interactions between the gut and other organs in systemic inflammation. Luminal components of the small intestine
can spread to the circulation via the portal vein (PV) and liver. This includes pro-inflammatory constituents such as lipopolysaccharide (LPS), bacterial
DNA, whole bacteria, other bacterial products, and free fatty acids (FFAs). Toxic components of the gut lumen, including FFAs, inflammatory products
of phospholipase A2 (PLA2), pro-inflammatory cytokines (e.g., IL-17), and damage-associated molecular substrates such as high mobility group box 1
protein (HMGB1), can reach the pulmonary circulation via mesenteric lymph. Bile acids from the liver, including cholic acid, DCA, and chenodeoxycholic
acid, mediate cytotoxic effects on intestinal epithelial cells. STAT3 signaling in Kupffer cells (KCs) of the liver maintains tolerance under homeostatic
conditions, whereas KCs produce high levels of pro-inflammatory cytokines in systemic inflammation with toxic effects on the lung parenchyma.
Finally, activated serine proteases, elastases, and lipases produced by the pancreas can cause local tissue destruction and activation of immune cells in
intestinal tissues, leading to exacerbated systemic inflammatory responses
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renal injury. Pharmacological or genetic approaches to
abrogate Paneth cell function reversed these effects
[111]. Similarly, genetic knockout for IL-17A also pre-
vented intestinal damage in this I/R model [112]. These
findings further demonstrate a central role for the gut
as a driving force in systemic inflammation (Fig. 2).
Finally, increased levels of alarmins that are generally
released after tissue injury were also found to be elevated
in post-shock mesenteric lymph [113]. These substrates
are endogenous TLR4 ligands and mediate immunostimu-
latory effects via the activation of nuclear factor kappa B
(NF-kB). Mice with genetic mutations in the receptors
or adapter molecules from the TLR4 signaling pathway
were protected against post-shock mesenteric lymph-
mediated lung injury [114]. These findings are consistent
with the “danger model” that states that certain endogen-
ous ligands signal the presence of tissue injury to the host
via PRRs [115], including TLR.
Conclusions
In conclusion, the mesenteric lymph is another route for
immunostimulatory proteins to reach the systemic circu-
lation after intestinal injury and post-shock mesenteric
lymph is particularly toxic to the pulmonary microvascu-
lature. Gut-derived toxic factors that leak from MLNs,
including products of pancreatic enzymes, endogenous
danger signals, and Paneth cell products, most likely
partner up to exert these detrimental effects. All the
aforementioned interactions are summarized in Fig. 3.
Finally, basic insights into the intimate relationship be-
tween the G-I tract and the systemic inflammatory system
are expected to lead to more efficacious treatment modal-
ities for critical illness in the future.
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